Sensitivity and Specificity of Rapid Diagnostic Tests for Hepatitis C Virus With or Without HIV Coinfection: A Multicentre Laboratory Evaluation Study

J Infect Dis. 2022 Aug 26;226(3):420-430. doi: 10.1093/infdis/jiaa389.

Abstract

Background: Hepatitis C virus (HCV) screening is critical to HCV elimination efforts. Simplified diagnostics are required for low-resource settings and difficult-to-reach populations. This retrospective study assessed performance of rapid diagnostic tests (RDTs) for detection of HCV antibodies.

Methods: Two lots of 13 RDTs were evaluated at 3 laboratories using archived plasma samples from 4 countries (Nigeria, Georgia, Cambodia, and Belgium). HCV status was determined using 3 reference tests according to a composite algorithm. Sensitivity and specificity were evaluated in HIV-infected and HIV-uninfected populations. Operational characteristics were also assessed.

Results: In total, 1710 samples met inclusion criteria. In HIV-uninfected samples (n = 384), the majority of RDTs had sensitivity ≥98% in 1 or both lots and most RDTs had specificity ≥99%. In HIV-infected samples (n = 264), specificity remained high but sensitivity was markedly lower than in HIV-uninfected samples; only 1 RDT reached >95%. The majority of HIV-infected samples for which sensitivity was low did not have detectable HCV viral load/core antigen. Interreader variability, lot-to-lot variability, and rate of invalid runs were low for all RDTs (<2%).

Conclusions: HCV RDTs should be evaluated in the intended target population, as sensitivity can be impacted by population factors such as HIV status.

Clinical trials registration: NCT04033887.

Keywords: HCV screening; hepatitis C virus; in vitro diagnostics; low- and middle-income country; rapid diagnostic test; sensitivity; specificity.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diagnostic Tests, Routine
  • HIV Infections* / epidemiology
  • Hepacivirus
  • Hepatitis C Antibodies
  • Hepatitis C* / complications
  • Hepatitis C* / diagnosis
  • Humans
  • Laboratories
  • Retrospective Studies
  • Sensitivity and Specificity

Substances

  • Hepatitis C Antibodies

Associated data

  • ClinicalTrials.gov/NCT04033887